open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:
Get Citation

11. The analysis of doses in the tumour and in critical tissues in the brachytherapy of malignant melanoma localised in eyes

J. Kierzkowski, J. Malicki, A. Roszak
DOI: 10.1016/S1507-1367(01)70381-1
·
Rep Pract Oncol Radiother 2001;6(1):31-32.

open access

Vol 6, No 1 (2001)
Untitled
Published online: 2001-01-01
Submitted:

Abstract

Brachytherapy is known and used procedure in the treatment of tumours localised in eyes, especially recommended when avoiding of enucleation accompany the long term cure.

Aim

The aim of this paper was to compare the doses delivered to the tumour and critical tissues during the treatment of the group of patients treated with Ru-106 applicator.

Patients

Between 1994 and 2000, 67 patients (dgn. melanoma malignum in eye) underwent brachytherapy. At 51 patients the tumour was localized in the back of eye, at 15 equatorially and at one in the front section of the eyeball. The median of the patients’ age was 56.3 years. The CCB type applicator was applied for 56 patients, the COB for 7 and the ROA for 4 patients.

Method

Irradiation – Prescribed dose of 60 Gy was normalized to the top of the tumour, it decreased by 50%—10% per millimetre with the distance from applicator. The isotope producer determined the dose-rate accuracy for +/−30%. This caused that therapeutic dose had to be calculated taking account for the minimal dose-rate, while the doses in critical organs for maximal dose-rate possible.

Analysis

All patients were divided into three subgroups: 8 patients into 1st, 19 into 2nd and 40 into 3rd. The inclusion criterion was size of tumour: up to 3 mm of height (1st group), 3–5 mm (2nd), and larger than 5 mm (3rd) respectively.

Results

Table presents mean doses in the tumour, sclera and lens (calculated at it's middle) for each group of patients.[[tgroup cols="4"]][[colspec colname="col1"/]][[colspec colname="col2"/]][[colspec colname="col3"/]][[colspec colname="col4"/]][[tbody]][[row]][[entry morerows="1" rowsep="1" align="center"]]Tumour size [mm][[/entry]][[entry namest="col2" nameend="col4" rowsep="1" align="center"]]Doses [Gy][[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]Tumour[[/entry]][[entry rowsep="1" align="center"]]Sclera[[/entry]][[entry rowsep="1" align="center"]]lens[[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]<3[[/entry]][[entry rowsep="1" align="center"]]102.9[[/entry]][[entry rowsep="1" align="center"]]162.4[[/entry]][[entry rowsep="1" align="center"]]137.6[[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]3–5[[/entry]][[entry rowsep="1" align="center"]]186.2[[/entry]][[entry rowsep="1" align="center"]]463.5[[/entry]][[entry rowsep="1" align="center"]]396.2[[/entry]][[/row]][[row]][[entry align="center"]]>5[[/entry]][[entry align="center"]]268.2[[/entry]][[entry align="center"]]974.9[[/entry]][[entry align="center"]]840.6[[/entry]][[/row]][[/tbody]][[/tgroup]]

Conclusions

Mean doses in tumour varied from 102.9 Gy to 268.2 Gy depending on the tumour size. Doses in sclera and lens did not exceed the tolerance levels in all three groups of patients.

Abstract

Brachytherapy is known and used procedure in the treatment of tumours localised in eyes, especially recommended when avoiding of enucleation accompany the long term cure.

Aim

The aim of this paper was to compare the doses delivered to the tumour and critical tissues during the treatment of the group of patients treated with Ru-106 applicator.

Patients

Between 1994 and 2000, 67 patients (dgn. melanoma malignum in eye) underwent brachytherapy. At 51 patients the tumour was localized in the back of eye, at 15 equatorially and at one in the front section of the eyeball. The median of the patients’ age was 56.3 years. The CCB type applicator was applied for 56 patients, the COB for 7 and the ROA for 4 patients.

Method

Irradiation – Prescribed dose of 60 Gy was normalized to the top of the tumour, it decreased by 50%—10% per millimetre with the distance from applicator. The isotope producer determined the dose-rate accuracy for +/−30%. This caused that therapeutic dose had to be calculated taking account for the minimal dose-rate, while the doses in critical organs for maximal dose-rate possible.

Analysis

All patients were divided into three subgroups: 8 patients into 1st, 19 into 2nd and 40 into 3rd. The inclusion criterion was size of tumour: up to 3 mm of height (1st group), 3–5 mm (2nd), and larger than 5 mm (3rd) respectively.

Results

Table presents mean doses in the tumour, sclera and lens (calculated at it's middle) for each group of patients.[[tgroup cols="4"]][[colspec colname="col1"/]][[colspec colname="col2"/]][[colspec colname="col3"/]][[colspec colname="col4"/]][[tbody]][[row]][[entry morerows="1" rowsep="1" align="center"]]Tumour size [mm][[/entry]][[entry namest="col2" nameend="col4" rowsep="1" align="center"]]Doses [Gy][[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]Tumour[[/entry]][[entry rowsep="1" align="center"]]Sclera[[/entry]][[entry rowsep="1" align="center"]]lens[[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]<3[[/entry]][[entry rowsep="1" align="center"]]102.9[[/entry]][[entry rowsep="1" align="center"]]162.4[[/entry]][[entry rowsep="1" align="center"]]137.6[[/entry]][[/row]][[row]][[entry rowsep="1" align="center"]]3–5[[/entry]][[entry rowsep="1" align="center"]]186.2[[/entry]][[entry rowsep="1" align="center"]]463.5[[/entry]][[entry rowsep="1" align="center"]]396.2[[/entry]][[/row]][[row]][[entry align="center"]]>5[[/entry]][[entry align="center"]]268.2[[/entry]][[entry align="center"]]974.9[[/entry]][[entry align="center"]]840.6[[/entry]][[/row]][[/tbody]][[/tgroup]]

Conclusions

Mean doses in tumour varied from 102.9 Gy to 268.2 Gy depending on the tumour size. Doses in sclera and lens did not exceed the tolerance levels in all three groups of patients.

Get Citation
About this article
Title

11. The analysis of doses in the tumour and in critical tissues in the brachytherapy of malignant melanoma localised in eyes

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 6, No 1 (2001)

Pages

31-32

Published online

2001-01-01

DOI

10.1016/S1507-1367(01)70381-1

Bibliographic record

Rep Pract Oncol Radiother 2001;6(1):31-32.

Authors

J. Kierzkowski
J. Malicki
A. Roszak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl